Health news
The Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of patients 12 years of age and older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of nivolumab,…
The Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the adjuvant treatment of adult and pediatric patients 12 years and older with stage IIB or IIC melanoma following complete resection. The indication for…
The Food and Drug Administration has accepted for Priority Review the Biologics License Application for the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients 12 years of age and…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021